ToplineStocks staged a Friday comeback, but still closed out a tough February, as the market’s post-election bump wobbled amid investors’ wavering faith in President Donald Trump’s economic policies, with Tesla, the car company led by Trump’s top deputy Elon Musk, leading the pullback.Traders work on the New York Stock Exchange floor on Monday.Getty Images Key FactsMajor indexes were positive Friday morning after the latest inflation data met economist forecasts – the blue chip Dow Jones Industrial Average, ...

Market Overview - The stock market is experiencing a downturn as investor confidence in President Trump's economic policies wanes, with Tesla leading the decline [1][5] - Major indexes showed a slight recovery on Friday morning, with the Dow Jones, S&P 500, and Nasdaq all rising approximately 0.6% after inflation data met forecasts [1] February Performance - February was a challenging month for U.S. equities, with the Dow down 2.3% (1,015 points), the S&P down 2.3%, and the Nasdaq down 4.8%, marking the worst month for the Dow and S&P since December and for the Nasdaq since September 2023 [2] - The S&P 500 has decreased by 1.6% since Trump's inauguration and 4% from its all-time high, although it remains up 2% since Election Day [3] Tesla's Decline - Tesla experienced a significant drop of 28% in February, resulting in a loss of approximately $360 billion in market capitalization, raising concerns about the impact of Elon Musk's political role on Tesla's sales [6] - Tesla's stock is currently trading about 40% below its all-time high from December, and it is on track for its second-worst month since going public in 2010 [6] Musk's Wealth - Elon Musk's net worth decreased from $422 billion to $358 billion in February, a decline of $64 billion, although he remains the richest person globally [7] Bitcoin's Performance - Bitcoin has also seen a decline, falling below $80,000 for the first time since November 10, down 25% from its all-time high set last month, although it recovered to around $84,000 by mid-morning [9]

Core Viewpoint - Financial 15 Split Corp. has announced an extension of its termination date from December 1, 2025, to December 1, 2030, allowing shareholders to continue benefiting from their investments [1]. Summary by Sections Company Overview - The Company provides leveraged exposure to a portfolio of high-quality financial services companies from Canada and the U.S. [2]. - The portfolio includes 15 financial services companies, such as Bank of Montreal, Royal Bank of Canada, and Goldman Sachs Group [6]. Shareholder Benefits - Class A shareholders have received total monthly distributions of $26.69 per share since the Company's inception [2]. - Preferred shareholders have received cumulative preferential monthly distributions totaling $12.19 per share since inception [3]. Tax Implications - The extension of the Company's term is not expected to trigger a taxable event, allowing shareholders to defer potential capital gains tax until they dispose of their shares [4]. Dividend Adjustments - The Company reserves the right to amend the minimum rate of cumulative preferential monthly dividends for Preferred Shares during the five-year renewal period, with any changes based on market yields announced by September 30, 2025 [5].

Financial Data and Key Metrics Changes - The company reported revenues of $732 million for the fiscal year 2024, a 14% increase compared to the prior year [7] - For Q4 2024, revenues were $186 million, reflecting a solid 5% year-over-year growth [7] - Gross margins decreased to 46.5% in Q4 2024 from 54% in Q4 2023, primarily due to increased costs and changes in sales structure [23] - Net income for Q4 2024 was $34 million or $0.74 per share, compared to $36.2 million or $0.68 per share in the previous year [25] Business Line Data and Key Metrics Changes - BAQSIMI sales grew 12% at the factory level, contributing $41.8 million to net product sales [20] - Primatene MIST sales reached $28.9 million in Q4 2024, an 18% increase from $24.5 million in the prior year [22] - Glucagon sales declined to $25.6 million from $31.2 million due to increased competition [22] - Epinephrine sales also decreased to $18.7 million from $24.6 million in the previous year [22] Market Data and Key Metrics Changes - The company anticipates continued unit growth in the high single-digit range for BAQSIMI following a 3% price increase in the U.S. [27] - Primatene MIST is expected to see high single-digit sales growth as the physician sampling program expands [27] - Increased competition is expected to lead to sales declines for glucagon, epinephrine, phytonadione, and enoxaparin [28] Company Strategy and Development Direction - The company is focusing on its branded and proprietary portfolio, with significant sales milestones achieved for Primatene MIST and BAQSIMI [18] - A strategic partnership with MannKind aims to enhance the sales reach of BAQSIMI [8] - The company plans to ramp up spending on clinical trials and expand its manufacturing capacity to support new product launches [30] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth potential of Primatene MIST and BAQSIMI, expecting them to be key revenue contributors through 2025 [11] - The company is preparing for potential approval of four key products in 2025, despite some delays [14] - Management noted that the vertically integrated business model positions the company well to mitigate impacts from trade policies [17] Other Important Information - The company plans to finance its expansion project with cash flow from operations and intends to continue stock buybacks [31] - Research and development expenditures decreased by 11% in Q4 2024, primarily due to lower spending on clinical trials [24] Q&A Session Summary Question: Outlook on Primatene MIST and glucagon for 2025 - Management expects high single-digit sales growth for Primatene MIST and anticipates unit volume drops for glucagon due to increased competition [34] Question: Preparedness for upcoming GDUFA dates - Management indicated that they may not be ready to launch new products until the quarter following their approval [37] Question: Impact of MannKind collaboration on BAQSIMI - The collaboration is expected to significantly increase the sales force, enhancing market coverage and potentially accelerating sales growth [56] Question: Competitive overview of epinephrine - The company remains the only player in the prefilled syringe market, while competition in the multi-dose vial segment has increased [58]

Financial Data and Key Metrics Changes - Consolidated revenue growth of 12.8% in Q4 2024, with operating income rising by 31.5% compared to the previous year [21] - Net consolidated income increased by 78.3% to nearly MXN 11 billion, driven by a non-cash change gain of MXN 2.7 billion and higher net income from discontinued operations of MXN 3.3 billion [21][22] - Gross margin expanded by 230 basis points to 47.7%, with operating margin increasing by 50 basis points to 11.7% of sales [25][26] Business Line Data and Key Metrics Changes - Proximity Americas division saw total revenues grow by 13.2%, with same-store sales growth of 3.8% despite a 2.8% decline in average traffic [24] - Health division revenues grew by 13.3%, with same-store sales increasing by 9.4% and operating income rising by 109.7% [29] - OXXO Gas reported a 9.7% increase in same-station sales and an 8% increase in total revenues [32] Market Data and Key Metrics Changes - Proximity Europe revenues increased by 21.5% in pesos, driven by retail revenue growth across countries [27] - Coca-Cola FEMSA recorded double-digit increases across their income statement, with income from operations rising by 25% [36] Company Strategy and Development Direction - FEMSA Forward initiative is nearing completion of planned divestitures, having monetized approximately $10.7 billion to focus on core business units [11][39] - Plans for 2025 include deploying nearly MXN 66 billion or $3.2 billion in capital returns, including ordinary and extraordinary dividends and share buybacks [14][15] - The company aims to maintain a disciplined approach to capital allocation, focusing on long-term intrinsic value per share [16] Management's Comments on Operating Environment and Future Outlook - Management acknowledges macroeconomic uncertainties and a softer consumer environment in Mexico, emphasizing the urgency to drive growth and profitability [46] - The company remains optimistic about growth opportunities across its business units, leveraging digital capabilities and operational efficiencies [10][46] Other Important Information - The succession process for the CEO position is underway, with a special committee formed to oversee the process [16][18] - The digital ecosystem has been rebranded as Spin, with significant growth in active users and sales linked to the loyalty program [34][35] Q&A Session Summary Question: Insights on shareholder remuneration and buybacks - Management plans to execute a mix of local buybacks in Mexico and accelerated share repurchases in the US, similar to previous years [55][56] Question: OXXO store expansion versus same-store sales trends - Management is confident in the ongoing expansion of OXXO stores, monitoring performance closely to ensure value creation [62][63] Question: Traffic decline attribution and operating leverage - Traffic decline is attributed to various factors, including weather and cannibalization, but management is confident in the store performance metrics [72][76] Question: Growth strategy in the US - The focus will be on organic growth through OXXO standalone stores and small bolt-on acquisitions, with an emphasis on profitability [90][91] Question: Financial services growth and potential banking license - The company is expanding financial services and plans to apply for a banking license, focusing on responsible growth in this area [100][101]

Core Insights - The article discusses the investment potential in companies with sustainable long-term competitive advantages, particularly in the technology, telecom, and banking sectors [1]. Company and Industry Analysis - The author emphasizes the importance of finding reasonably priced businesses that possess sustainable competitive advantages, which is crucial for long-term investment success [1]. - The focus is on large global brands within the technology, telecom, and banking sectors, indicating a preference for established companies with strong market positions [1].

Financial Data and Key Metrics Changes - Total revenue for 2024 was $208 million, a decrease from $217 million in 2023 [30] - Software revenue grew by 13.3% from $159 million to $180 million, with hosted revenue increasing from $20 million to $35 million [30][34] - Q4 total revenue was $88.3 million, an increase of 19% compared to Q4 2023 [18] - Q4 software revenue was $79.7 million, up 16% from Q4 2023 [19] - The net loss for 2024 was $187 million or $2.57 per diluted share, compared to a net income of $41 million or $0.54 per diluted share in 2023 [34] Business Line Data and Key Metrics Changes - The number of software customers with an annual contract value (ACV) greater than $5 million increased from 4 to 8, while those with ACV greater than $1 million rose from 27% to 31% [12] - Total ACV increased by 24% to $191 million [12] - Drug discovery revenue for 2024 was $27 million, down from $58 million in 2023 [32] Market Data and Key Metrics Changes - Hosted revenue contributed 20% of software revenue for 2024, compared to 13% in 2023 [30] - The software gross margin for the year was 79.5%, down from 81.5% in 2023 [32] Company Strategy and Development Direction - The company aims to drive continued increases in the adoption of its computational technology and enterprise informatics platform in 2025 [13] - Plans to release several new products and solutions, including predictive toxicology technology and enhancements to biologics discovery technologies [14] - The company is optimistic about the broad momentum continuing into 2025, with expectations for software revenue growth in the range of 10% to 15% [36] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's position for a transformational 2025, with strong operational, financial, and strategic foundations [40] - The company does not expect significant growth from the Chinese market, which represents less than 5% of revenue [39] Other Important Information - The company reported a cash and marketable securities balance of $367 million at the end of Q4 2024, down from $469 million at the end of Q4 2023 [35] - The predictive toxicology project is expected to contribute significantly to revenue in 2025 [41] Q&A Session Summary Question: What is your assumption behind your 2025 drug discovery revenue guidance? - The increase in drug discovery revenue is broad-based, with contributions from various collaborations, including the Novartis partnership [57] Question: How should we think about the cadence for drug discovery revenues? - Drug discovery revenues are likely to be somewhat back-end weighted, with contributions scaling up throughout the year [125] Question: What do customers consider when moving from on-prem to hosted? - The transition to hosted contracts is seen as more seamless for delivering licenses, and the company expects a gradual increase in hosted revenue [76][78] Question: What are the stickiest aspects driving customer retention? - Customer retention is driven by the technology's impact on projects, leading to improved quality and faster development of candidates [90] Question: What is the gating factor for advancing new clinical candidates? - The company is currently evaluating potential partnerships for its clinical assets, with ongoing discussions as data becomes available [114]

Company Performance - Bank of America (BAC) closed at $43.94, showing no movement from the previous day, while the S&P 500 gained 0.01% [1] - Over the past month, BAC shares have declined by 6.19%, underperforming the Finance sector's loss of 0.09% and the S&P 500's loss of 2.26% [1] Upcoming Earnings - The upcoming earnings disclosure is anticipated to show an EPS of $0.81, reflecting a 2.41% decline compared to the same quarter last year [2] - Revenue is expected to reach $26.71 billion, indicating a 3.47% increase from the year-ago quarter [2] Fiscal Year Estimates - For the entire fiscal year, earnings are projected at $3.70 per share, with revenue estimated at $108.36 billion, representing increases of +12.8% and +6.36% respectively from the previous year [3] Analyst Estimates - Recent changes to analyst estimates suggest a favorable outlook on Bank of America's business health and profitability [4] - A 0.34% rise in the Zacks Consensus EPS estimate has been noted over the past month, with Bank of America currently holding a Zacks Rank of 3 (Hold) [6] Valuation Metrics - Bank of America has a Forward P/E ratio of 11.88, which is below the industry average of 13.86 [7] - The current PEG ratio for BAC is 1.19, compared to the industry average PEG ratio of 1.15 [7] Industry Context - The Financial - Investment Bank industry, part of the Finance sector, holds a Zacks Industry Rank of 3, placing it in the top 2% of over 250 industries [8]

Financial Data and Key Metrics Changes - In Q4 2024, GMV reached $5.4 billion, showing flat year-over-year growth in US dollars and an 11% increase in FX-neutral terms [39] - Revenue totaled $61.5 million, growing 1% year-over-year in US dollars and 12% in FX-neutral for Q4 2024, while full-year revenue reached $226.7 million, representing 13% and 18% growth in US dollars and FX-neutral respectively [40][94] - Subscription revenue for Q4 2024 was $59.5 million, a 2% increase in US dollars and 13% in FX-neutral, with full-year subscription revenue at $217.7 million, up from $190.3 million in 2023, indicating 14% and 20% growth in US dollars and FX-neutral [43][97] Business Line Data and Key Metrics Changes - The number of customers generating over $250,000 in annual recurring revenue increased by 23%, while annual revenue churn remained stable in the mid-single digits [58] - Existing stores' revenue increased to $169 million, with a net revenue retention rate of 104% in FX-neutral [98][100] - Subscription gross margin improved to 78.9% in Q4 2024, up from 78.6% in the same period last year [104] Market Data and Key Metrics Changes - Revenue generated outside Brazil accounted for 43.4% of total revenues in 2024, with Brazil's subscription revenue growing 28% in FX-neutral [101][102] - Latin America excluding Brazil saw a 6% increase in subscription revenue in FX-neutral, while the Rest of the World subscription revenue grew 34% in FX-neutral [102] Company Strategy and Development Direction - VTEX aims to transition from a single product platform to an integrated suite of solutions, expanding its offerings to include B2C, B2B, Sales App, and more [72] - Strategic investments in AI and conversational commerce capabilities, including a stake in Synerise and the acquisition of Weni, are intended to enhance VTEX's product suite and market position [18][73] - The company is focused on building trust with customers and delivering on promises, positioning itself as a comprehensive commerce suite for enterprises [19][73] Management's Comments on Operating Environment and Future Outlook - Management acknowledged challenges in Brazil due to softer consumer spending and currency devaluation but expressed confidence in sustaining profitable growth through new customer acquisitions and product innovations [41][96] - The company targets FX-neutral year-over-year subscription revenue growth of 13% to 15% for Q1 2025 and 14% to 17% for the full year 2025 [56][57] - Management remains optimistic about future opportunities despite short-term growth rate challenges, emphasizing strong operational indicators [57][58] Other Important Information - A new share-repurchase program was approved, allowing the repurchase of up to $30 million in Class A common shares [108] - The company repurchased 1.8 million Class A common shares at an average price of $6.08 per share, totaling $11.2 million in Q4 2024 [108] Q&A Session Summary Question: What are the expectations for subscription revenue growth in 2025? - The company is targeting FX-neutral year-over-year subscription revenue growth of 13% to 15% for Q1 2025 and 14% to 17% for the full year 2025 [56][57] Question: How is the company addressing the challenges in Brazil? - Management highlighted the importance of new customer acquisitions and product innovations to sustain growth despite the challenging consumption environment in Brazil [41][96] Question: What strategic investments has the company made recently? - VTEX made strategic investments in AI and conversational commerce capabilities, including a stake in Synerise and the acquisition of Weni, to enhance its product offerings [18][73]

Employee Engagement and Compensation - The Corporation employed approximately 213,000 employees as of December 31, 2024, with 78% located in the U.S.[15] - Compensation and benefits expense for the Corporation was $40.2 billion in 2024, representing 60% of total noninterest expense[15] - In 2024, the Corporation hired over 18,000 new employees, reflecting a diverse range of backgrounds[17] - The Employee Engagement Index was 84% in 2024, with 87% of employees participating in the annual survey[19] - The Corporation's minimum hourly wage for U.S. employees was increased to $24 per hour in October 2024, with a goal of reaching $25 per hour by 2025[21] - Approximately 97% of employees globally will receive Sharing Success compensation awards in the first quarter of 2025[21] - The Corporation delivered approximately 7.6 million hours of training and development to employees through Bank of America Academy in 2024[18] - The turnover rate among employees was stable at 8% in both 2024 and 2023[19] - U.S. health insurance premiums remained unchanged for employees earning less than $50,000 for the 12th consecutive year[24] - The Corporation's commitment to equal pay for equal work is reinforced by third-party reviews overseen by the Board[22] Regulatory Compliance and Financial Stability - The FDIC's Deposit Insurance Fund (DIF) ratio is currently below the statutory minimum of 1.35% and the long-term goal of 2%[37] - In October 2022, the FDIC adopted a restoration plan that includes a 2 basis points increase in deposit insurance assessments across the industry[37] - The Corporation's stress capital buffer (SCB) increased to 3.2% based on the results of the 2024 Comprehensive Capital Analysis and Review (CCAR) stress test[41] - The Corporation's global systemically important bank (G-SIB) surcharge increased to 3.0% on January 1, 2024[41] - As of June 30, 2024, the Corporation held greater than 10% of the total amount of deposits of insured depository institutions in the U.S.[58] - The Corporation's liabilities did not exceed 10% of the total liabilities of all financial institutions in the U.S. as of June 30, 2024[59] - The Volcker Rule restricts banking entities from engaging in short-term proprietary trading and imposes limits on investments in hedge funds and private equity funds[60] - The Corporation is subject to extensive regulation and oversight by federal and state regulators regarding consumer finance laws[63] - The Corporation is required to submit a resolution plan every two years due to its status as a bank holding company with assets greater than $250 billion[45] - The FDIC may be appointed receiver of an insured depository institution if it is insolvent, allowing for an orderly liquidation under certain circumstances[53]